Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Homoharringtonine in Acute Promyelocytic Leukemia
ChiCTR-TRC-09000504Phase 4Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2009
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of homoharringtonine in Acute promyelocytic leukaemia (APL) (4 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: disease free survival, complete remission and 2 more. Started Aug 2009; status: completed.
02
Drugs
homoharringtonine
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on ChiCTR-TRC-09000504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000504.